SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Roger Cranwill who wrote (987)6/15/1997 11:47:00 PM
From: Vector1   of 1762
 
Roger and everone else on this thread,
I have been lurking on this thread for about a week. During that time I have been researching IDEC and Coulter trying to decide which is the better play. No question IDEC has a high likelihood of getting C2B8 approved and when that happens the stock will have a nice pop. It is definitely an advantage to be first.
On the other hand, Coulter's Bexxar has had tremendous early clinical results and it appears that a radiopharma conjugated to a MA has a compounding effect on efficacy. Bexxar has not only had a high respose rate but has resulted in complete remission in almost 50% of patients where chemo has failed. That is very impresssive. There is a big difference between response and complete remission. Moreover from what I have read the side efects of Bexxar are not substantially greater than C2B8. Thus if Bexxar is approved I would respectively disagree with the agrument that C2B8 will be the drug of choice with respect to NHL that is chemo resistent. These are people who are fighting for their lives and I have little doubt they and their Oncologists will want to use the most efficous compound. This is of course why IDEC has been working so hard on their own MA with a conjugated radiopharma(Y2B8). Has anyone on the thread had an opportunity to review any data on this compound. I have read a post that suggested that it will be more efficous than Bexxar with fewer side effects. Why is this the case.
This is an excellent thread and I look forward to your resonse.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News